Survivin is a multifunctional protein. It has been shown to inhibit apoptosis, to regulate cell division, and to enhance angiogenesis, see [1]. Studies have shown the expression of Survivin in non-muscle invasive bladder cancer to associate with progression to muscle-invasive disease, see [2]–[5]. Survivin has also been investigated in several other cancers. It has been discussed whether total, nuclear, or cytoplasmic Survivin expression should be evaluated in relation to clinical outcome. When using this protocol, we focus on the nuclear expression of Survivin.
This APP can be used for quantifying the nuclear expression of Survivin. The approach to calculating expression used here, was demonstrated to have a statistically significant correlation to manual scoring in a study involving 300 patients (publication pending).